双鹭药业前三季度实现营业收入4.59亿元 净利润同比增943.1%

Core Viewpoint - Beijing Shuanglu Pharmaceutical Co., Ltd. reported a significant increase in net profit for the first three quarters of 2025, despite a decline in revenue, primarily due to changes in the fair value of financial assets [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 459 million yuan, a year-on-year decrease of 15.13% [1] - The net profit attributable to shareholders reached 141 million yuan, marking a substantial year-on-year increase of 943.1% [1] Reasons for Performance Fluctuation - The notable increase in net profit is attributed to a rise in the fair value change gains from trading financial assets, including holdings in Shouyao Holdings and Xinghao Pharmaceutical [1] - From January to September 2024, the company recorded a fair value change loss of 122 million yuan, while in the same period of 2025, it reported a fair value change gain of 128 million yuan, reflecting a year-on-year growth of 204.93% [1]